Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level-Reference-Cited by-同舟云学术

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

Published:2009-08 Issue:2 Volume:83 Page:154-155
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Huang Jocelin,Tefferi Ayalew

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2009.01266.x/fullpdf

Reference10 articles.

1. Erythropoietin after a century of research: younger than ever;Jelkmann;Eur J Haematol,2007

2. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial;Cazzola;Blood,1992

3. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia;Barosi;Br J Haematol,1993

4. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin;Hasselbalch;Am J Hematol,2002

5. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia;Tefferi;Br J Haematol,1994

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis;Blood Advances;2024-08-28

2. SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. PDE6G inhibits the expression of CD71 in erythroid progenitor cells through the PDE6G/BHLHE40/miR144-3p/CD71 pathway, leading to red cell production obstacles and ultimately causing anemia in myelofibrosis;2024-05-28

4. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices;American Journal of Hematology;2024-01-02

5. Cytopenic myelofibrosis: prevalence, relevance, and treatment;Expert Opinion on Pharmacotherapy;2023-04-17